An observational study in Behavioral Variant of Frontotemporal Disorder (bvFTD), Phenocopy Frontotemporal Dementia (phFTD) and Frontal Variant of Alzheimer Disease, sponsored by Nantes University Hospital. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-29.
Sponsored by Nantes University Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 104 studies in Bipolar Disorder with a site in France — 34 open to participants now, 38 under way, 1 of them phase 3. Bipolar Disorder · France.
Among the 104 studies in Bipolar Disorder with a site in France, this one is the 12th largest by planned enrollment of the 25 observational ones that give a count, is one of 7 that started in 2023, is one of 25 observational ones, reaches primary completion later than 15 of the 37 other live ones, and was the 85th registered.
1,687 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.
Browse Bipolar Disorder studies →34 of the 104 studies in Bipolar Disorder with a site in France are open now. Recruiting first, the newest first:
CHU de Reims · Sites in France
Ages 18–65 · Healthy volunteers
Centre Hospitalier St Anne · Sites in France
Ages 18+
Fondation FondaMental · Sites in France
Ages 15–60 · Healthy volunteers
Hospital Center Guillaume Régnier · Sites in France
Ages 18+
University Hospital, Montpellier · Sites in France
Ages 18–45 · Healthy volunteers
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 207 Bipolar Disorder studies recruiting now, 60 (29%) set no upper age limit and 134 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
104 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 5 · Phase 3 16 · Phase 4 2
First in 2004; this study’s year is marked. 7 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 120 is below the median of 158 across 349 observational studies indexed under Bipolar Disorder.
Median enrollment 170 across the 79 interventional studies, 100 across the 25 observational. Of the 46 that completed or were terminated, 12 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
25 of 104 have an industry lead sponsor. The 10 most frequent:
Nantes University Hospital is the lead sponsor of 839 studies on the registry; 189 are open to participants now.
Nantes University Hospital has 2 studies filed under Bipolar Disorder — fewer than ten, so there is no comparison to draw.
10 of the studies in Bipolar Disorder with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07140913Phase 3Bristol-Myers SquibbA Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine | 2027-06-28 |
| NCT07316803Centre hospitalier de Ville-Evrard, FranceGroup Intervention for Romantic Relationships in Young Adults With Severe Mental Illness | 2026-11-30 |
| NCT04917419Centre Hospitalier Henri LaboritNursing Care of Bipolar Patients With Sleeping Disorders Using Luminotherapy and /or Psychoeducation Program (BIPLUMINO) | 2026-12 |
| NCT05878730Assistance Publique - Hôpitaux de ParisMelatonin and Response to Lithium | 2026-12 |
| NCT06059313Nantes University HospitalPremorbid Personality Profile of Patients With Cognitive and Behavioral Disorders | 2026-12-14 |
Add all 10 to your calendar (.ics) → With an account.
Among the 104 studies in Bipolar Disorder with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Damages in frontal area present in neurodegenerative disease (frontotemporal degeneration, frontal variant of Alzheimer disease) and in psychiatric disease (bipolar disorder) can affect behavior and cognition including social cognition. Symptoms vary both quantitatively and qualitatively from disease to another and from person to person. It cannot be completely excluded that in some cases, factors of susceptibility such as premorbid personality traits lead to frontal fragility.
The study will assess the relationship between premorbid profile using NEO-PI 3 inventory and cognitive and behavioral/psychobehavioral manifestations in patients with behavioral variant of frontotemporal disorder (bvFTD), phenocopy frontotemporal dementia (phFTD), frontal variant of Alzheimer disease, bipolar disorder characterized with frontal damages.
The study will be conducted among eligible patients with bvFTD, fvAD, phFTD, followed to Memory Resource and Research Centre at Nantes university Hospital CMRR or referred to the department for a neuropsychological assessment (bipolar disorder). It will prospectively enroll 120 participants.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria :
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A group of participants who fulfill Rascovsky criteria (2011) for behavioural variant Frontotemporal Dementia
Other: Submission of the NEO-PI-3 questionnaire · Other: Submission of the Interpersonal Reactivity Index questionnaire (IRI)
A group of participants who fulfill who fulfill Rascovsky criteria (2011) for possible behavioural variant Frontotemporal Dementia and have no imaging abnormalities.
Other: Submission of the NEO-PI-3 questionnaire · Other: Submission of the Interpersonal Reactivity Index questionnaire (IRI)
A group of participants who fulfill Ossenkopele criteria (2022)
Other: Submission of the NEO-PI-3 questionnaire · Other: Submission of the Interpersonal Reactivity Index questionnaire (IRI)
A group of participants who fulfill CIM 10 criteria
Other: Submission of the NEO-PI-3 questionnaire · Other: Submission of the Interpersonal Reactivity Index questionnaire (IRI)
The questionnaire contains 240 statements. For each statement, the patient chooses the answer that best corresponds to their choice (FD: strongly disagree - D: disagree - N: neutral - A: agree - FA: strongly agree).
The test assesses two cognitive and two affective components of empathy that influence each other and affect attitudes and behaviors toward others.
Premorbid personality traits
Premorbid personality traits will be assessed by the NEO- NEO Personality Inventory-3 (NEO-PI-3). The NEO PI-3 measures the five major domains of personality: Neuroticism, Extraversion, Openness to experience, Conscientiousness and Agreeableness. Each domain is defined by 6 facets. NEOPI-3 includes 240 items and responses are made on a 5-point Likert -type scale ranging from strongly Disagree to strongly agree. The NEOPI 3 will be completed by a caregiver who has known the patient in the 10 years preceding the disease onset.
Time frame: Baseline
Interpersonal Reactivity Index (IRI)
IRI is a 28-item questionnaire measuring 4 aspects of empathy : perspective-taking, fantasy, empathic concern, personal distress. Each answer is rated from 1 (does not describe me well) to 5 (describes me very well).
Time frame: Baseline
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2023 (actual). Primary completion is estimated for Dec 2026, 36 months after the start.
Of 95 non-industry observational studies under Bipolar Disorder, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 119. This study's planned 36 months is below that.
Counting every sponsor, half of 105 studies reached it within 64 months; a quarter within 31 and three quarters within 119.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.